SITC 2026 has ended. This guide stays up as the record of who was there. Next: SITC 2027, Nov 3–7, 2027 in National Harbor

Pharma and biotech companies at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

159 pharma and biotech companies are at SITC 2026 — 222 presentations on the program and 13 with a booth in the exhibit hall. Most represented: Merck & Co. (8 on the program), AstraZeneca (7 on the program), Kite Pharma (4 on the program). 159 of them have their own page in this guide. As of Nov 2, 2026.

All 661 organizations at SITC 2026 →

Research topic
Top represented
Showing 1–6 of 159 organizations
OrganizationSITC 2026 Attendance
Merck & Co.
Rahway, NJ
Large pharma
Global pharmaceutical company, known as MSD outside the US and Canada, running a broad oncology research and clinical development program.
Booth
Exhibiting at Booth 1228
Fri, Nov 610:00am–2:00pm · 5:00pm–7:00pmSat, Nov 710:00am–2:00pm · 6:00pm–8:10pm
Session
Wed Nov 4
3:10pm–3:55pm
Session
Thu Nov 5
12:00pm–1:30pm
Session
Thu Nov 5
6:45pm–7:20pm
Session
Fri Nov 6
3:55pm–5:30pm
Biotech Session: The Next Generation of Off-the-Shelf IO
Cell therapy
  1. 3:55pm–4:10pmTargeting PRAME with IMA402, a Novel Bispecific T-Cell Engager (TCER) - Initial Clinical ResultsImmatics
  2. 4:10pm–4:25pmIn vivo Cell Therapy Platforms for CancerEli Lilly and Company
  3. 4:25pm–4:40pmAllogeneic CAR T: A Platform Built for Patient Access – in Cancer and BeyondAllogene Therapeutics
  4. 4:40pm–4:50pmTargeted LNP Delivery of an RNA Gene Writer Enables In Vivo Generation of Functional CAR-T Cells in Non-human PrimatesTessera Therapeutics
  5. 4:50pm–5:00pmSTEALTH-001: A Phase 1 Study of VET3-TGI, an Oncolytic Vaccinia Virus Encoding TGFb Inhibitor and IL-12, for the Treatment of Advanced Solid TumorsUPMC Hillman Cancer Center
  6. 5:00pm–5:30pmIn Vivo - Ex Vivo DebateKite Pharma, Massachusetts Institute of Technology, Roswell Park Comprehensive Cancer Center, Azalea Therapeutics
AstraZeneca
Cambridge, United Kingdom
Large pharma
Global biopharmaceutical company that discovers, develops and sells prescription medicines, with oncology among its main therapy areas.
Booth
Exhibiting at Booth 801
Fri, Nov 610:00am–2:00pm · 5:00pm–7:00pmSat, Nov 710:00am–2:00pm · 6:00pm–8:10pm
Workshop
Wed Nov 4
2:00pm–5:00pm
Biotech Regulatory Roundtable
  1. 2:00pm–2:10pmOpening Remarks: SITC Biotech Initiative: A Quest for 100 Novel Agents
  2. 2:10pm–2:55pmPanel Discussion 1: Conversations with FDA Oncology Leaders on Hot Topics
  3. 2:55pm–3:10pmNetworking Break
  4. 3:10pm–3:55pmPanel Discussion 2: Biomarker Discovery and Digital AI
  5. 3:55pm–4:10pmNetworking Break #2
  6. 4:10pm–4:55pmPanel Discussion 3: Regulatory Framework for New IO Agents
  7. 4:55pm–5:00pmClosing Remarks
Session
Thu Nov 5
12:00pm–1:30pm
Poster
Sat Nov 7
12–1:30pm
6:40–8:10pm
Kite Pharma
Santa Monica, CA
Biotech
Gilead-owned company developing and marketing CAR T-cell therapies for blood cancers.
Workshop
Thu Nov 5
8:00am–4:15pm
New Agents in Development and Emerging Technologies
  1. 8:00am–9:50amSession I: Cell Therapies and Technologies
  2. 10:05am–11:50amSession II: Immune Cell Engagers and Bispecifics
  3. 1:30pm–2:55pmSession III: ADC/iADC
  4. 3:10pm–4:15pmSession IV: Emerging Technologies – Incorporation into Clinical Trials
Workshop
Thu Nov 5
8:00am–9:50am
Session I: Cell Therapies and Technologies
Cell therapy
  1. 8:05am–8:25amCAR-T Lessons Learned Guiding Next Gen Cell Therapies
  2. 8:25am–8:35amIn vivo CAR Technologies
  3. 8:35am–8:45amFrom Antigen Selection to Clinical Activity: What PRAME is Teaching us About TCR T-cell Therapy in Solid TumorsImmatics
  4. 8:45am–8:55amEngineering Regulatable Cytokine Signaling for Next-generation TIL cell TherapiesObsidian Therapeutics
  5. 8:55am–9:05amExploiting Tumor Hypoxia for CEA CAR-T Therapy in Colorectal Cancer: From Biological Rationale to Clinical TranslationThe First Affiliated Hospital, Zhejiang University School of Medicine
  6. 9:05am–9:15amAdvancing a First-in-Class Allogeneic CAR T Approach in Renal Cell Carcinoma: Clinical Experience from the TRAVERSE StudyAllogene Therapeutics
  7. 9:15am–9:25amGPC3 Targeting ARTEMIS T Cell Therapy in Advanced HCCEureka Therapeutics
Pfizer
New York, NY
Large pharma
Global pharmaceutical company with an oncology portfolio that includes antibody-drug conjugates from its Seagen acquisition.
Workshop
Wed Nov 4
2:00pm–5:00pm
Biotech Regulatory Roundtable
  1. 2:00pm–2:10pmOpening Remarks: SITC Biotech Initiative: A Quest for 100 Novel Agents
  2. 2:10pm–2:55pmPanel Discussion 1: Conversations with FDA Oncology Leaders on Hot Topics
  3. 2:55pm–3:10pmNetworking Break
  4. 3:10pm–3:55pmPanel Discussion 2: Biomarker Discovery and Digital AI
  5. 3:55pm–4:10pmNetworking Break #2
  6. 4:10pm–4:55pmPanel Discussion 3: Regulatory Framework for New IO Agents
  7. 4:55pm–5:00pmClosing Remarks
Workshop
Wed Nov 4
3:10pm–3:55pm
Workshop
Wed Nov 4
4:55pm–5:00pm
Large pharma
Global pharmaceutical company whose immuno-oncology medicines include the checkpoint inhibitors nivolumab and ipilimumab.
Session
Thu Nov 5
6:45pm–7:20pm
AT
Ankyra Therapeutics
Cambridge, MA
Biotech
Develops anchored immunotherapies designed to keep cytokine drugs at the tumor injection site.
Session
Thu Nov 5
12:00pm–1:30pm
Workshop
Thu Nov 5
7:00pm–8:00pm
Early Career Scientist Speed Mentoring
  1. 7:00pm–8:00pmSpeed Mentoring - Group Mentoring
  2. 7:00pm–7:30pmSpeed Mentoring - One-on-One
  3. 7:30pm–8:00pmSpeed Mentoring - One-on-One 2
Session
Fri Nov 6
12:30pm–1:30pm
Rapid Oral - Clinical 1
Clinical
  1. 12:30pm–12:38pmTranscriptional Phenotypes in Basal Keratinocytes Predict Immunotherapy Responsiveness in Cutaneous Squamous Cell CarcinomaStanford University
  2. 12:38pm–12:46pmIntralesional PD-1 Blockade Induces Localized Immune Mobilization and Coordinated Lymphatic Niche Assembly in High-Risk Oral Premalignant LesionsUC San Diego
  3. 12:46pm–12:54pmEVX-01 personalized AI-designed vaccine plus pembrolizumab induce neoantigen-specific T-cell responses and systemic immune modulation in advanced melanomaEvaxion
  4. 1:00pm–1:08pmTargeting IL-1-associated myeloid inflammation to intercept lung precancers: Translational studies and interim results of a Phase 2 trialIcahn School of Medicine at Mount Sinai
  5. 1:08pm–1:16pmSGLT2 inhibitors and incretin-based therapies are associated with increased immune-related toxicity reporting during cancer immunotherapyMayo Clinic
  6. 1:16pm–1:24pmHLA and non-HLA genetic risk are predictive of development of immune checkpoint inhibitor induced diabetesUCSF

Explore the full SITC 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Phoenix. Leave your work email and we’ll be in touch.

Privacy

Download the full SITC 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from pharma and biotech companies

Tell us what you sell and we’ll find the people at these pharma and biotech companies most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse SITC 2026 by

Exhibit hall

Not affiliated with or endorsed by the Society for Immunotherapy of Cancer (SITC). Submit a correction